Zydus Pharmaceuticals, USA, signed a license and supply agreement with Italy's CHEMI SpA or CHEMI - a subsidiary of Italfarmaco Group, to launch the Enoxaparin Sodium injection in the United States (US). The injection is usually given to patients undergoing abdominal, knee or hip replacement surgery.
The product is a generic equivalent of Sanofi Aventis's branded product Lovenox, according to a regulatory filing by Cadila Healthcare to the stock exchanges today. Zydus Pharma Inc, USA is a 100 percent subsidiary of Cadila Healthcare Limited or Zydus Cadila.
As part of the agreement, CHEMI will manufacture and supply the Enoxaparin Sodium injection which Zydus Cadila will commercialize in the United States. Utilising their proprietary technology, CHEMI will produce the Enoxaparin Sodium injection within the proprietary manufacturing facilities situated in Italy.
The leading specialty pharmaceutical company owns the proprietary rights on a pharmaceutical product composed of preservative-free Enoxaparin Sodium single-use pre-filled syringes, according to the statement.
The Enoxaparin Sodium injection is used for the treatment of deep vein thrombosis or DVT in patients undergoing abdominal, hip, or knee replacement surgery. The injection is also given for the treatment of acute DVT. Enoxaparin acts as a blood thinner by producing an antithrombotic effect, added Cadila Healthcare in its statement. The injection had annual sales of approximately $513 million in the United States, according to IQVIA data as of June 2021.
On Friday, August 20, shares of Cadila Healthcare were last trading 1.43 per cent lower at Rs 534.95 on the BSE. Cadila Healthcare opened on the BSE at Rs 540, inching to an intra day high of Rs 547.85 and an intra day low of Rs 522, in the session so far.